AZD 1208

Drug Profile

AZD 1208

Alternative Names: AZD1208

Latest Information Update: 10 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene proteins c pim 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer
  • Discontinued Acute myeloid leukaemia; Lymphoma; Solid tumours

Most Recent Events

  • 01 Apr 2017 Preclinical trials in Prostate cancer in USA, before April 2017
  • 01 Apr 2017 Adverse events and pharmacodynamics data from a preclinical trial in Prostate cancer presented at the 108th annual meeting of the American Association for Cancer Research (AACR-2017)
  • 30 Sep 2014 Discontinued - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in USA and Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top